Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Tipo del documento
Asunto de la revista
País de afiliación
Intervalo de año de publicación
1.
J Thromb Thrombolysis ; 57(4): 650-657, 2024 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-38491266

RESUMEN

BACKGROUND: The interrelation of cancer with venous thromboembolism is established, yet the specific impact on the incidence and progression of superficial vein thrombosis (SVT) remains unclear. OBJECTIVES: To investigate the association between SVT and malignancies, focusing on risk factors, presentation, course and complications. METHODS: A single-center prospective observational study of patients diagnosed with DVT or SVT referred to a venous thromboembolism clinic between January 2013 and April 2018. RESULTS: Of the 632 patients, 205 presented with SVT at referral, 16.6% having active cancer. Significant associations were found between active cancer and the risk of developing proximal SVT (RR 1.54 [1.18-2.03] p < 0.01), SVT within 3 cm from junction (RR 2.01 [1.13-3.72] p = 0.019), bilateral SVT (RR 8.38 [2.10-33.43] p < 0.01) and SVT affecting multiple veins (RR 2.42 [1.40-4.20] p < 0.01), with a higher risk of persistence (RR 1.51 [1.18-1.95] p < 0.01) and progression (RR 5.75 [2.23-14.79] p < 0.01) at initial assessment. Patients with SVT and no malignancy history demonstrated an elevated risk for new-onset cancer during follow-up (RR 1.43 [1.13-1.18] p = 0.022), especially in cases of proximal or bilateral SVT, initial progression or subsequent DVT or PE. No significant differences were observed in persistence, recurrence or complications during initial evaluation or follow-up across different pharmacological treatments. CONCLUSIONS: Research suggests a probable link between cancer history and the development of SVT. SVT presented more severely in cancer patients. SVT, especially in its more complex forms, could serve as a predictive marker for the future development of cancer. Treatment approaches varied, no significant differences in outcomes were noted.


Asunto(s)
Neoplasias , Tromboembolia Venosa , Trombosis de la Vena , Humanos , Tromboembolia Venosa/tratamiento farmacológico , Anticoagulantes/uso terapéutico , Trombosis de la Vena/diagnóstico , Factores de Riesgo , Neoplasias/complicaciones
2.
Rev. clín. med. fam ; 15(1): 63-66, Feb. 2022. ilus
Artículo en Español | IBECS (España) | ID: ibc-209826

RESUMEN

El tumor miofibroblástico inflamatorio (TMI) es un tumor del estroma submucoso raro cuya presentación más frecuente es en el pulmón. Se trata de un tumor heterogéneo, formado por células fusiformes, inflamatorias y miofibroblastos, que por lo general es benigno, pero puede producir invasión local, recidiva y transformación maligna. Presentamos un paciente joven con una neoplasia en la lengua de aspecto invasivo e infiltrante que resultó ser un tumor miofibroblástico, pero que causó gran preocupación por su rápido crecimiento.(AU)


An inflammatory myofibroblastic tumour is a rare submucosal stromal tumour whose most common presentation is in the lung. This is a heterogeneous tumour, comprised of spindle cells, inflammatory cells and myofibroblasts, which is generally benign. However, it can cause local invasion, recurrence and malignant transformation. We report a young patient with an invasive and infiltrating tumour on the tongue that turned out to be a myofibroblastic tumour but caused major concern due to its rapid growth.(AU)


Asunto(s)
Humanos , Masculino , Adulto , Pacientes Internos , Examen Físico , Evaluación de Síntomas , Neoplasias de Tejido Muscular , Lengua/lesiones , Neoplasias de la Lengua/diagnóstico , Lengua/cirugía , Medicina Familiar y Comunitaria , Enfermedades de la Lengua/diagnóstico , Tabaquismo , Patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA